{
    "pmcid": "9461429",
    "qa_pairs": {
        "How many unique nanobodies targeting the SARS-CoV-2 spike protein were isolated in the study?": [
            "37 unique nanobodies",
            "25 unique nanobodies",
            "50 unique nanobodies",
            "10 unique nanobodies"
        ],
        "What are the potential applications of nanobodies beyond therapeutic use as mentioned in the study?": [
            "Diagnostic applications for detecting and monitoring SARS-CoV-2 infections",
            "Vaccine development for SARS-CoV-2",
            "Gene therapy for SARS-CoV-2",
            "Antiviral drug formulation for SARS-CoV-2"
        ],
        "What are the structural and functional benefits of nanobodies compared to traditional monoclonal antibodies in targeting SARS-CoV-2?": [
            "Nanobodies have a small size, stability, and ability to access cryptic epitopes.",
            "Nanobodies have a larger size, making them more effective in binding.",
            "Nanobodies are less stable but have a higher affinity for viral proteins.",
            "Nanobodies are derived from human antibodies, increasing their specificity."
        ],
        "What was the observed reduction in viral loads in hamster models when using selected Fc-fused nanobodies?": [
            "Up to six orders of magnitude",
            "Up to two orders of magnitude",
            "Up to eight orders of magnitude",
            "Up to four orders of magnitude"
        ],
        "Which SARS-CoV-2 variants did the nanobodies demonstrate broad neutralization capabilities against?": [
            "Alpha, Beta, Gamma, Delta, and Omicron",
            "Alpha, Beta, Epsilon, and Zeta",
            "Gamma, Delta, Lambda, and Mu",
            "Omicron, Theta, Iota, and Kappa"
        ]
    }
}